Eur J Cancer Care (Engl):去势难治性前列腺癌骨转移患者中心理压力与疼痛减轻没有相关性

2019-06-14 AlexYang MedSci原创

驱使难治性前列腺癌(CRPC)患者中,骨转移疼痛能够引起生活质量的降低(QoL)。在具有骨转移症状的CRPC患者中,镭-223治疗与良好的生存益处和骨疼痛显著减轻相关。最近,有研究人员评估了镭-223治疗期间,疼痛减轻与心理压力之间的相关性。研究总共包括了63名具有mCRPC的患者,他们均经历了镭-223治疗,并且对他们详细的说明了改善疼痛和增加生存的可能性。研究人员利用简要疼痛量表数值评定量表对

驱使难治性前列腺癌(CRPC)患者中,骨转移疼痛能够引起生活质量的降低(QoL)。在具有骨转移症状的CRPC患者中,镭-223治疗与良好的生存益处和骨疼痛显著减轻相关。最近,有研究人员评估了镭-223治疗期间,疼痛减轻与心理压力之间的相关性。

研究总共包括了63名具有mCRPC的患者,他们均经历了镭-223治疗,并且对他们详细的说明了改善疼痛和增加生存的可能性。研究人员利用简要疼痛量表数值评定量表对疼痛反应进行了评估,并利用EORTC QoL调查问卷中的C30和BM22条目对心理压力进行了评估。研究发现,疼痛强度在首次镭-223治疗后显著减少(-1.03点,p=0.0032),之后在整个治疗期间维持稳定(-1.30点,p≤0.001)。而在镭-223治疗期间心理状态并没有表现出明显的变化,且也没有发现心理状态与疼痛减轻之间的相关性。

最后,研究人员指出,晚期PC患者中,镭-223的骨疼痛治疗与心理状态的改善没有关系。他们的研究强调了心理在QoL评估中的影响以及利用多学科方法详细评估患者情绪作用的必要性。

原始出处


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
    2020-01-04 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
    2019-10-22 haouestc
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
    2019-06-16 freve
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2081563, encodeId=128a2081563ce, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 04 03:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837696, encodeId=bb22183e696ba, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 14 23:07:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785546, encodeId=efb21e8554690, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Oct 22 12:07:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528572, encodeId=746615285e2d1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630816, encodeId=606f1630816db, content=<a href='/topic/show?id=96875113eb4' target=_blank style='color:#2F92EE;'>#心理压力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51137, encryptionId=96875113eb4, topicName=心理压力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3e721584542, createdName=yuanming14, createdTime=Sun Jun 16 04:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040477, encodeId=2b6510404e7d9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Jun 14 16:07:00 CST 2019, time=2019-06-14, status=1, ipAttribution=)]
    2019-06-14 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Oncogene:脂多糖激活的鞘氨醇激酶能够促进前列腺癌细胞的侵入和转移

在前列腺炎和前列腺癌(PCa)组织中,主要的细菌群体是革兰氏阴性细菌,脂多糖(LPS)是革兰氏阴性细菌的重要化合物,在一些癌症类型中具有激活活性,但是到目前为止在PCa中还没有完整的研究。最近,有研究人员调查了LPS对PCa细胞入侵的影响。有趣的是,LPS能够增强PCa的侵入性,但对PCa细胞活性没有显著的影响。研究人员通过前列腺抑制剂筛选和生化分析,基质酶,一种膜锚定丝氨酸蛋白酶家族的成员,被发

BMC Cancer:前列腺癌和小细胞癌谱系关系研究

前列腺癌具有不同的形态,而这些不同的形态可以影响患者的治疗结果。这个情况促使了人们思考分化的、可以治疗的前列腺癌与分化不良、不太可能治疗的癌症(包括小细胞癌)之间的关系以及前列腺癌分化的潜在分子机制。最近,有研究人员利用非恶性肿瘤/小细胞癌PDX LuCaP细胞系进行了干细胞转录因子(scTF)LIN28A、NANOG、POU5F1和SOX2的表达分析。研究发现,scTF在小细胞癌LuCaP 93

Radiology:用MRI指标探前列腺癌前列腺外侵犯之病理之实!

本研究旨在评价前列腺癌病理证实前列腺外侵犯(EPE)相关的MRI征象,并提出病理学EPE MRI分级系统。

新型晚期前列腺癌靶向诊疗技术在英国首次上市

这项名为Theranostics的技术为前列腺癌和神经内分泌肿瘤(包括头颈癌)的治疗和诊断提供了个性化的治疗,现在该服务已在英国GenesisCare中心首次上市。

Sci Rep:前列腺癌中应激诱导隧道纳米管利于治疗适应性

隧道纳米管(TNTs)是基于肌动蛋白的膜结构,可以将远距离的细胞物理上联系起来,从而进行细胞间的交流。最近,有研究人员确定了前列腺癌(PCa)中,TNTs在应激诱导适应性和治疗抵抗性中的作用。雄激素受体(AR)阻断和代谢应激能够诱导TNTs,但是在正常前列腺上皮或者成骨细胞中不存在上述情况。共培养试验分析阐释了在应激和非应激条件下,PCa细胞的TNT形成的增强,从应激的PCa细胞到造骨细胞TNT形

Prostate Cancer P D:[68Ga] Ga-PSMA 11 PET在淋巴结中检测前列腺癌的表现研究

生化复发(BCR)前列腺癌(PCa)患者的节点复发挽救性淋巴结清扫(sLND)在当前的指南中仍旧不推荐,主要是由于当前传统成像的不准确性造成。最近,研究人员评估了[68Ga] Ga-PSMA 11 PET(PSMA-PET)在检测PCa淋巴结转移中的表现,并通过sLND进行了病理学确认。研究人员对MEDLINE、SCOPUS、Web of Science和Cochrane Library进行了搜索